TNFRSF1A and Parkinson disease: XPro1595 has been shown to provide beneficial effects in animal models of several peripheral and CNS inflammatory conditions, including experimental autoimmune encephalomyelitis, Parkinson’s disease, spinal cord injury, and focal cerebral ischemia, by selectively inhibiting sTNFα-TNFR1 signaling and sparing beneficial functions of TNFR2 (McCoy et al., 2006; Zalevsky et al., 2007; Brambilla et al., 2011; Clausen et al., 2014; Novrup et al., 2014).